Focused Ultrasound Treatment of Skin and Soft Tissue Abscesses
- Institution
- University of Washington, WA
- Principal investigator
- Thomas Matula
- Funding
- $683K
- Duration
- 2022–2027
Moonbase score
Still being scored
Abstract
Skin and soft tissue infections (SSTIs) are among the most common infections encountered in ambulatory and inpatient settings with cellulitis and abscess being most common. Effective treatments are needed as SSTIs are a high-volume condition, and the overall healthcare burden remains high. SSTIs are one of the top causes for hospital readmissions. Furthermore, the standard of care, incision and drainage (I&D), is one of the most painful procedures in the emergency department. In addition to pain and the potential for unsightly scarring, other complications from I&D include damage to surrounding structures, an extension of the infection into adjacent tissues, bacteremic complications and reoccurrence. Furthermore, patient populations with psychosocial risk factors (e.g., homelessness, IV drug use) are prone to secondary infections and wound care remains problematic in these populations. Although bacteria can develop drug resistance, they remain susceptible to mechanical damage. In particular, short intense pulses of Focused Ultrasound (FUS), histotripsy, non-invasively generates localized cavitation that mechanically disrupts the bacteria and represents a new paradigm for non- invasive abscess treatment. We propose that histotripsy can non-invasively disinfect and liquefy many superficial and intramuscular abscesses allowing for complete fine needle aspiration. Our Aims are to expand our animal model to include MRSA pathogens and perform animal studies to advance this technology toward first in human studies. If successful, this approach could decrease patient morbidity, eliminate hospital stays, and lower healthcare costs.
LOADING MOONBASE SCORE
Questions for University of Washington
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · University of Washington66
NextGen Long-acting and targeted combination ART for Children with HIV
Rodney J.Y. Ho · $1.4M · 2020–2026
- NIH · University of Washington63
TLR7/8 agonist design and delivery for effective anticancer immune response
Jayanth Panyam · $350K · 2021–2026
- NIH · University of Washington63
Rare Mutations and Autism Spectrum Disorders
Evan Eichler · $758K · 2013–2026